Results 151 to 160 of about 4,566 (176)
Cancers, 2023 Background: Recent studies have shown that low-density lipoprotein receptor-related protein 1b (LRP1B), as a potential tumor suppressor, is implicated in the response to immunotherapy. The frequency of LRP1B mutation gene is high in many cancers, but its role in gastric cancer (GC) has not been determined.
Aiguagn Zhao, Nida Cao, Mengmeng Qin
exaly +4 more sources
LRP1B—A Prognostic Marker in Tubo-Ovarian High-Grade Serous Carcinoma [PDF]
Human Pathology, 2023 Low-density lipoprotein (LDL) receptor-related protein 1B (LRP1B) is a member of the LDL receptor family and has often been discussed as a tumor suppressor gene, as its down-regulation is correlated with a poor prognosis in multiple carcinoma entities.
Eliane T Taube +2 more
exaly +4 more sources
Using a Dual CRISPR/Cas9 Approach to Gain Insight Into the Role of LRP1B in Glioblastoma
International Journal of Molecular Sciences, 2023 LRP1B remains one of the most altered genes in cancer, although its relevance in cancer biology is still unclear. Recent advances in gene editing techniques, particularly CRISPR/Cas9 systems, offer new opportunities to evaluate the function of large genes, such as LRP1B.
Joana Peixoto +2 more
exaly +4 more sources
Cancers, 2022 SIMPLE SUMMARY: Immune checkpoint inhibitors (ICIs) changed the standard care of patients with lung squamous cell carcinoma (LUSC). It is an urgent need to precisely predict the population’s response to ICIs.
Zhipeng Zhou, Xiaonan Wu, Jiangyong Yu
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
LRP1B Deletion Is Associated With Poor Outcome for Glioblastoma Patients
Journal of the Neurological Sciences, 2015Deletion of the tumor suppressor gene LRP1B has been reported in glioblastoma, the most aggressive primary brain tumor in adults. Our objective was to analyze frequency and prognostic impact of LRP1B deletion and expression levels.We retrospectively included all the primary IDH1/2 wild-type GBM patients with available clinical follow-up, DNA and RNA ...
Emeline Tabouret +2 more
exaly +3 more sources
LRP1B and GRM3 expression in colorectal cancer.
Journal of Clinical Oncology, 2022177 Background: LRP1B is a member of the low-density lipoprotein receptor family and a tumor suppressor found to be downregulated in colon cancer (CRC). GRM3 is a receptor of glutamate, an amino acid and neurotransmitter. Inhibition of GRM3 reduces CRC cell growth. Recent data from CALGB/SWOG 80405 suggests that mutations (MT) of either LRP1B or GRM3
Priya Jayachandran +17 more
openaire +1 more source
Biomarkers in Medicine, 2022 Background: The aim of this study was to discover unique membrane proteins associated with gastric cancer (GC) in proteomics analysis. Methods: Using a data-independent acquisition strategy, we compared the relative expression levels of membrane proteins in GC.
Peng Song, Chao Ding, Ji Miao
exaly +3 more sources
Analysis of LRP1B as a potential biomarker for colorectal cancer immunotherapy.
Journal of Clinical Oncology, 2021e15521 Background: Low-density lipoprotein receptor-related protein 1B (LRP1B), a putative tumor suppressor, is one of the most frequently altered gene in cancer. Recently, there are emerging evidences that LRP1B is involved in sensitivity to melanoma and non-small cell lung cancer immunotherapy.
Ruiting Liu, Qianqian Duan, Qin Zhang
openaire +1 more source
Pathobiology, 2021 <b><i>Background:</i></b> Pegylated liposomal doxorubicin (PLD) is among the most active therapies for recurrent/progressive ovarian cancer (OC). Low-density lipoprotein receptor-related protein 1B (LRP1B) is one of the 10 most significantly deleted genes in human cancers.
Paula Soares, Hugo Prazeres
exaly +3 more sources